Alfred’s participation in a clinical trial has stabilized his cancer, allowing him to cherish more moments with his loved ones
London: In 2012, Alfred found out he had advanced prostate cancer that had spread to his bones. It was a tough blow, and surgery wasn’t an option. So, he decided to join the STAMPEDE trial funded by Cancer Research UK, which was testing a drug called abiraterone.
Luckily, Alfred responded really well to the treatment, and now his cancer is stable. He’s super grateful, saying, “If it wasn’t for abiraterone, I don’t think I’d be here today.” He believes Cancer Research UK uses its funds wisely and deserves support.
When he first got the news about his cancer, all he could think was, “How long do I have?” It was tough to hear, and even harder to share with his wife and kids. But learning about the STAMPEDE trial gave him a glimmer of hope. He’s thankful to everyone who supports Cancer Research UK.
It’s interesting to note that gifts in Wills fund about a third of Cancer Research UK’s work, which helps support life-saving trials like the one Alfred participated in. Last year, nearly 8,000 people pledged gifts in their Wills to help fight cancer, which has helped double survival rates in the UK.
However, with 1 in 2 people facing a cancer diagnosis in their lifetime, there’s still a lot of work to do. By leaving a gift in your Will, you can help fund new ways to tackle cancer and create a future where everyone can live longer, healthier lives without the fear of cancer.
Abiraterone was discovered by researchers at the Cancer Research UK Centre for Cancer Therapeutics. They played a key role in its early trials and development. Alfred’s participation in the STAMPEDE trial was crucial, and it’s a testament to the importance of research in fighting cancer.
